RT Journal Article
T1 Increased soluble Fas plasma levels in subjects at high cardiovascular risk - Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST
A1 Blanco-Colio, Luis M
A1 Martín-Ventura, Jose L
A1 Teresa Galván, Eduardo,de
A1 Farsang, Csaba
A1 Gaw, Allan
A1 Gensini, GianFranco
A1 Leiter, Lawrence A
A1 Langer, Anatoly
A1 Martineau, Pierre
A1 Hérnandez, Gonzalo
A1 Egido, Jesús
K1 inflammation
K1 atorvastatin
K1 soluble Fas
K1 C-reactive protein
K1 statins
K1 Anticolesterolemiantes
K1 Antígenos CD95
K1 Proteína C-Reactiva
K1 Enfermedades Cardiovasculares
K1 Diabetes Mellitus
K1 Relación Dosis-Respuesta a Droga
K1 Proteína Ligando Fas
K1 Femenino
K1 Regulación de la Expresión Génica
K1 Ácidos Heptanoicos
K1 Humanos
K1 Masculino
K1 Síndrome X Metabólico
K1 Mediana Edad
K1 Estudios Prospectivos
K1 Pirroles
AB OBJECTIVEIncreasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment.METHODS AND RESULTSACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk > 20%. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides < or = 600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85% of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL.CONCLUSIONSsFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.
PB Lippincott, Williams & Wilkins
SN 1079-5642
YR 2007
FD 2007-01
LK http://hdl.handle.net/10668/826
UL http://hdl.handle.net/10668/826
LA en
NO Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler. Thromb. Vasc. Biol.. 2007                         ; 27(1):168-74
NO Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 19, 2025